ok I went and looked anyway. It does say that there is a benefit if the doses are pooled. Not quite sure what that means, but it does tend to indicate that the issue is a little more complex than you portray it to be. Again.
Dana On 12/4/05, Dana <[EMAIL PROTECTED]> wrote: > > tsk as usually you are poo pooing without reading. You'd be funny if you > weren't so condescending. The attitude of real science indeed. > > Hello, I am talking about anticoagulation, as Sam has already realized. > Remember that the next time you call him a Neanderthal. > > As for your study, don't have time. It may say this but given your track > record I am willing to bet it says more than that too. In any event there > are other studies, peer-reviewed, my friend. See the archives; posted them > this summer. Ther aren't a lot -- there are problems with establishing a > standard does as I have already mentioned. > > Dana > > > > On 12/4/05, Larry C. Lyons <[EMAIL PROTECTED]> wrote: > > > > I think that this Cocheran based meta analysis summarizes the attitude > > of real science, there is no real effect for ginko beyond a placebo. > > > > http://www.antiwrap.com/?789 > > > > Ginkgo biloba Compared with Cholinesterase Inhibitors in the Treatment > > of Dementia: A Review Based on Meta-Analyses by the Cochrane > > Collaboration > > A. Kurza, B. Van Baelenb > > > > aDepartment of Psychiatry and Psychotherapy, Technical University > > Munich, Munich, Germany; > > bMedisearch International, Mechelen, Belgium > > > > Dementia and Geriatric Cognitive Disorders 2004;18:217-226 (DOI: > > 10.1159/000079388) > > > > Abstract > > > > Data were derived from the Cochrane Collaboration meta-analyses of the > > efficacies of ginkgo, donepezil, rivastigmine and galantamine on > > changes in cognitive function in patients with dementia and, where > > necessary, were transformed to standardized mean differences. The > > proportion of patients discontinuing trials was used as a proxy > > measure of tolerability. Outcomes were assessed after 6 months of > > treatment. Trial data for cholinesterase inhibitors were more > > consistent than those for ginkgo, particularly regarding patient > > populations and outcome measures. Significant benefits on cognition > > vs. placebo were seen with donepezil, 5 and 10 mg, rivastigmine, 6-12 > > mg, and galantamine, 16 and 24 mg. Significant benefit vs. placebo > > with ginkgo was seen only when all doses were pooled. Similar > > proportions of patients discontinued treatment with ginkgo and > > placebo. Cholinesterase inhibitors were also well tolerated, although > > a significantly greater proportion of patients receiving active > > treatment discontinued vs. placebo with some doses. An evidence-based > > medicine approach, taking into account the quality of clinical trials, > > is essential when assessing the safety and efficacy of medications. > > -- > > > > ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~| Find out how CFTicket can increase your company's customer support efficiency by 100% http://www.houseoffusion.com/banners/view.cfm?bannerid=49 Message: http://www.houseoffusion.com/lists.cfm/link=i:5:185683 Archives: http://www.houseoffusion.com/cf_lists/threads.cfm/5 Subscription: http://www.houseoffusion.com/lists.cfm/link=s:5 Unsubscribe: http://www.houseoffusion.com/cf_lists/unsubscribe.cfm?user=11502.10531.5 Donations & Support: http://www.houseoffusion.com/tiny.cfm/54
